Synonyms:doxorubicin, Adriamycin, 23214-92-8, Doxil, Doxorubicine, Adriblastina, Doxorubicinum, 14-Hydroxydaunomycin, 14-Hydroxydaunorubicine, Doxorubicine [INN-French], Doxorubicinum [INN-Latin], Doxorubicina [INN-Spanish], Doxorubicin Hydrochloride, Caelyx, Adriamycin semiquinone, Hydroxydaunorubicin, Adriablastin, UNII-80168379AG, FI 106, CHEMBL53463, Doxorubicina, CHEBI:28748, (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione, NDC 38242-874, NCI-C01514, 80168379AG, ADM, (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside, (1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside, Doxorubicin [USAN:INN:BAN], ThermoDox, 25316-40-9, DOX, MLS000028393, DM2, Doxorubicin-hLL1, (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside, (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione, (7S,9S)-7-[(4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione, (8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione, (8S-cis)-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione, Adriblastina (TN), CCRIS 739, Doxorubicin-P4/D10, HSDB 3070, 111266-55-8, EINECS 245-495-6, Doxorubicin (USAN/INN), Doxorubicin-hLL1 conjugate, Doxorubicin-P4/D10 conjugate, 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-, NSC-123127, (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride, (8S,10S)-10-(((2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracen, Prestwick0_000438, Prestwick1_000438, Prestwick2_000438, Prestwick3_000438, ADR, Probes1_000151, Probes2_000129, SCHEMBL3243, BSPBio_000456, BSPBio_001031, (1S,3S)-3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-(3-amino-2,3,6-tridesoxy-alpha-L-lyxo-hexopyranosid), (8S,10S)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione, 1,2,3,4,6,11-Hexahydro-4beta,5,12-trihydroxy-4-(hydroxyacetyl)-10-methoxy-6,11-dioxonaphthacen-1beta-yl-3-amino-2,3,6-trideoxy-alpha-L-lyxohexopyranoside, 10-((3-Amino-2,3,6-trideoxy-D-lyxohexopyranosyl)oxy)-8-glycolcyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione, Caelyx (liposomal doxorubicin), SPBio_002395, BPBio1_000502, cid_443939, GTPL7069, Valrubicin impurity, doxorubicin, DTXSID8021480, BDBM22984, BDBM32022, HMS2089H06, ZINC3918087, GR-319, HY-15142A, LMPK13050001, MFCD00869292, AKOS015951330, Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74, Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120, DB00997, MCULE-4188577717, SMP1_000106, NCGC00024415-35, NCGC00024415-37, NCGC00024415-38, NCGC00024415-40, NCGC00024415-41, NCGC00024415-42, NCGC00024415-61, BP-23114, 14D928, A14403, C01661
Pubchem:PUBCHEM:31703
Id:7815b8a2-44a1-5c94-93c8-c4ed3fa54aa2
Description:nan
